The Journal. The Wall Street Journal
-
- News
-
The most important stories about money, business and power. Hosted by Kate Linebaugh and Ryan Knutson, with Jessica Mendoza. The Journal is a co-production of Spotify and The Wall Street Journal.
Get show merch here: https://wsjshop.com/collections/clothing
-
New York’s U-Turn on a Plan to Reduce Traffic
The nation’s first congestion-pricing plan was set to take effect at the end of June. But last week, New York Gov. Kathy Hochul called to indefinitely delay the program. WSJ's Jimmy Vielkind unpacks the surprising move and explores why Hochul made the 11th hour change.
Further Reading:
-New York Gov. Kathy Hochul Abruptly Halts Manhattan Congestion Pricing
Further Listening:
-NYC’s Food Delivery Workers Fight for a Minimum Wage
-New York City's 'De Facto Ban' on Airbnb
Learn more about your ad choices. Visit megaphone.fm/adchoices -
Shein: Fast Fashion, Slow IPO
The fast-fashion giant hoped to have a splashy U.S. public offering this year. WSJ's Shen Lu explains how the divide between Beijing and Washington got in the way.
Further Reading:
- Shein Promised to Have a Big U.S. IPO. Its China Roots Got in the Way.
- Fast-Fashion Giant Shein Files to Go Public
Further Listening:
- Shein Took Over Fast Fashion. Then Came the Backlash.
- The Mysterious CEO Leading Shein to an IPO
Learn more about your ad choices. Visit megaphone.fm/adchoices -
Trillion Dollar Shot, Episode 4: The Disruptors
The rising popularity of GLP-1 drugs could cause all kinds of ripple effects.
According to one estimate, 9% of the U.S. population could be on Ozempic or similar medications by 2030. Meanwhile, drugmakers are already developing the next generation of weight-loss drugs and researchers are studying the possible health benefits beyond weight loss and diabetes, including addiction.
In the final episode of our series we ask: What could all this development mean for businesses, from the food sector to airlines? And who wins and who loses in the post-Ozempic economy?
Guests include: David Ricks, CEO of Eli Lilly; and Mehdi Farokhnia, an addiction researcher at the National Institutes of Health.
Listen to Episodes 1, 2 and 3 of “Trillion Dollar Shot” here.
Learn more about your ad choices. Visit megaphone.fm/adchoices -
‘It Came out of Nowhere’: The Rise of Dr Pepper
There is a new contender in the cola wars, and it isn’t a cola. It’s Dr Pepper. WSJ’s Jennifer Maloney unpacks how after decades as a distant competitor, Dr Pepper has climbed the soda ranks with help from hefty marketing, novel flavors and TikTok videos.
Further Reading:
- Dr Pepper Ties Pepsi as America’s No. 2 Soda
Further Listening:
- The Agony and Ecstasy of Tab
Learn more about your ad choices. Visit megaphone.fm/adchoices -
Why Biden Is Cracking Down on Asylum at the Border
President Biden unveiled a last-ditch effort to lower illegal crossings at the southern border this week. The move focuses on asylum seekers, and the policy is similar to one that former President Trump tried in 2018. WSJ’s Michelle Hackman describes the policy and tries to answer the question: why now?
Further Reading:
-Biden Issues Executive Actions on Immigration: What to Know
Further Listening:
-What the End of Title 42 Means for U.S. Immigration Policy
-What Trump's Immigration Restrictions Could Mean for the Economy
Learn more about your ad choices. Visit megaphone.fm/adchoices -
Behind Closed Doors, Biden’s Age is Showing
For much of his career, Biden built a reputation as a master negotiator. He’s known for his detailed knowledge of issues—and for hitting his stride when the pressure was on. Now, 81-year-old Biden is the oldest person to hold the presidency. WSJ's Annie Linskey and Siobhan Hughes go behind closed doors where some who have worked with him describe a president who appears slower.
Further Reading:
- Behind Closed Doors, Biden Shows Signs of Slipping
Further Listening:
- Inside the White House's Scramble to Avert a Bigger Middle East War
Learn more about your ad choices. Visit megaphone.fm/adchoices
Customer Reviews
I love this pod :)
This is one of my fav pods I like to listen to it in the background when I draw . I want to learn more about the economy and how to prevent inflation and other economical issues :D
Also I do saw the other reviews. I wasn’t paying too much attention but based on others’ opinions, perhaps you could address this?
Good information
Thank for your work
Easy to understand and quick
Ozempic advertising?
I listed to all four of the “shot” episodes and was disappointed in the lack of serious journalism and clear language. For example, in the final episode, there was a significant discussion about the potential ancillary benefits of the weight loss drug, e.g., heart, etc. But from my readings, it’s not the drugs, but the weight loss itself, that’s causing these benefits. The whole thing just felt like n Ozempic/et al ad without hard questions.